CD19 and systemic lupus erythematosus: Recent studies show that CD19 CAR T-cell therapy can induce drug-free remission in refractory SLE and idiopathic inflammatory myopathies, with only mild, short-lived cytokine release syndrome as a well-tolerated side effect (11, 12).